Product Information
CITALOPRAM HBR 10 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.0260 per EA under NDC 65862000501. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 28, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862000501
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CITALOPRAM HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077031FDA Approved
10/28/2004
TE Code
AB
On Market Since
10/28/2004
Pharmacological Classes
Price Statistics
The NADAC for CITALOPRAM HBR 10 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 23.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0260 per EA |
|---|---|
| All-time high | $0.0389 (Feb 12, 2014) |
| All-time low | $0.0204 (May 22, 2024) |
| 52-week high | $0.0260 |
| 52-week low | $0.0240 |
| Median price | $0.0277 |
| Average price | $0.0291 |
| Largest weekly change | +24.2% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Citalopram Hydrobromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CITALOPRAM HBR 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CITALOPRAM HBR 10 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.0260 per EA (NDC 65862000501), effective Sep 30, 2026.
How has the price of CITALOPRAM HBR 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for CITALOPRAM HBR 10 MG TABLET has declined 23.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CITALOPRAM HBR 10 MG TABLET?
Since Nov 28, 2013, the NADAC for CITALOPRAM HBR 10 MG TABLET has ranged from a low of $0.0204 (May 22, 2024) to a high of $0.0389 (Feb 12, 2014), with a median of $0.0277 per EA.
Are there cheaper alternatives to CITALOPRAM HBR 10 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CITALOPRAM HBR 10 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CITALOPRAM HBR 10 MG TABLET?
CITALOPRAM HBR 10 MG TABLET (NDC 65862000501) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.